Nebenwirkungen · Benlysta
Benlysta 120 mg powder for concentrate for solution for infusion. Benlysta 400 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 58
HOS-124015 · Präparat HOS-095751
Psychiatric disorders: In the pre-registration intravenous SLE clinical studies, serious psychiatric events were reported in 1.2 % (8/674) of patients receiving Benlysta 10 mg/kg body weight and 0.4 % (3/675) of patients receiving placebo. Serious depression was reported in 0.6 % (4/674) of patients receiving Benlysta 10 mg/kg body weight and 0.3 % (2/675) of patients receiving placebo. There were two suicides in Benlysta- treated patients (including one receiving Benlysta 1 mg/kg body weight).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T14:51:00Z · SHA-256 c5a3f583695e2640a8d21bbd8da1102adfb181d1d2a9c5afe0028436c8fd2402 · Passage 3e9cd42e7c31e7ff4b48bfa14ca444ea419d7a73a90866e1669578f07fe0e896 · Zeichen 8894–9393 im Abschnitt